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Abstract
Over the last few years, the importance of the resident 
intestinal microbiota in the pathogenesis of several gastro-
intestinal diseases has been largely investigated. Growing 
evidence suggest that microbiota can influence gastro-
intestinal motility. The current working hypothesis is that 
dysbiosis-driven mucosal alterations induce the production 
of several inflammatory/immune mediators which affect 
gut neuro-muscular functions. Besides these indirect 
mucosal-mediated effects, the present review highlights 
that recent evidence suggests that microbiota can directly 
affect enteric nerves and smooth muscle cells functions 
through its metabolic products or bacterial molecular 
components translocated from the intestinal lumen. Toll-
like receptors, the bacterial recognition receptors, are 
expressed both on enteric nerves and smooth muscle and 
are emerging as potential mediators between microbiota 
and the enteric neuromuscular apparatus. Furthermore, 
the ongoing studies on probiotics support the hypothesis 
that the neuromuscular apparatus may represent a target 
of intervention, thus opening new physiopathological and 
therapeutic scenarios.
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Core tip: This article reviews the current evidence of gut 
microbiota and neuromuscular apparatus connection 
that results to be both direct and indirect. Besides 
dysbiosis-driven mucosal inflammatory mediators, 
recent evidence suggests that gut neuromuscular 
apparatus can be modulated directly by microbiota 
metabolic products or circulating bacterial molecular 
components translocated from the intestinal lumen. 
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INTRODUCTION
Microbiota and gut motility are clearly associated, 
but it’s difficult to establish what plays the major role 
in influencing the other. According to the classical 
theory, gastrointestinal (GI) motility can affect the 
microbiota in terms of amount, location and diversity. 
This concept is mainly supported by the association 
between different GI motility disorders and small 
intestinal bacterial overgrowth (SIBO)[1,2]. GI motility 
disorders and alterations of migrating motor complex 
(MMC), that eliminates residual content through 
the GI tract during periods of fasting, predispose to 
SIBO because bacteria are not swept from the small 
bowel into the colon, as reported in experimental 
models and specific clinical conditions[3-5]. Neuropathic 
and myopathic diseases, such as scleroderma and 
polymyositis, seem to be associated with SIBO[1,6] as 
well as conditions associated to long-standing diabetes, 
such as gastroparesis[7].
On the other hand, both in vivo and in vitro evidence 
highlights that microbiota can affect GI motility[8,9]. In 
studies conducted on germ-free animals, impairment 
of neural and motor functions of the GI tract due to 
reduced expression of neurotransmitters and contractile 
proteins, were reversed by gut colonization[10]. Moreover, 
probiotics have been shown to affect GI motility in 
vivo and in vitro. Prebiotic or probiotic therapies are 
associated with a significant clinical improvement in 
irritable bowel syndrome (IBS)[11,12] and animal studies 
suggest that the neuromuscular apparatus could 
represent a target for probiotics[13-15]. Finally, dysbiosis 
is associated with significant alterations in intestinal 
transit time[16].
By interacting directly with mucosal environment, 
the microbiota impacts intestinal mucosal functions 
and permeability, and influences local and systemic 
inflammatory activity[12]. In normal conditions 
neuromuscular apparatus is not in contact with the 
luminal content and quite inaccessible by the luminal 
microbes. However, dysbiotic conditions cause an 
increase in mucosal inflammation and intestinal 
paracellular permeability[17,18] (Figure 1) with possible 
translocation of pathogens, toxins, antigens and 
bacteria in the circulatory system[16,19,20]. GI motility 
might then be affected by microbiota essentially by 
two mechanisms: an indirect mechanism driven by 
the inflammatory mediators released by the mucosal 
immune system and a direct mechanism driven 
both by the release of end products of bacterial 
fermentation and bacterial substances. 
INDIRECT EFFECTS
The potential for the microbiota to produce inflam-
matory alterations in the gut microenvironment 
deranging gastrointestinal motor function prompts to 
a unifying hypothesis for the role of the microbiota 
in the pathogenesis of IBS. To support a role 
of the microbiota in IBD pathophysiology is the 
evidence that an acute episode of gastroenteritis 
precedes the onset of IBS, a specific condition 
called post-infectious IBS (PI-IBS)[11,21,22]. PI-IBS is 
characterized by persistent abdominal discomfort, 
bloating and diarrhea, despite the elimination of 
the causative pathogen. In this condition, the imba-
lance in microbiota composition leads to low-grade 
inflammation followed by alteration of the sensory 
and motor bowel functions. An increased amount of 
immune cells in the colonic, ileal, and jejunal mucosa 
of IBS patients has been largely reported[23,24]. The 
persistent inflammatory state is also characterized by 
increased mucosal interleukin 1β levels and mast cells 
count, as well as activation of entero-endocrine cells 
(EC), mainly those producing serotonin (5-HT)[25-28]. 
The interesting data is that most of these mucosal 
alterations persist for over a year and thus could 
contribute to the persistence of a PI-IBS. Therefore, 
the mucosal inflammation resulting from an acute 
infection can lead to a dysfunction of intestinal 
motility and 5-HT could play a pivotal role as its 
release increases motility and secretion, features 
which may explain diarrheal symptoms frequent in 
PI-IBS patients[29]. With an experimental model of 
primary infection with Trichinella spiralis, that causes 
hypercontractility of intestinal muscle persisting 
for over 20 d after the infection was cleared, it was 
shown that chronic immune response may extend 
to smooth muscle layers[30]. In this model, the 
levels of Th2 cytokines (interleukins 4, 5, and 13) 
resulted increased during the acute infection but 
not thereafter, whereas cyclooxygenase-2 (COX-2) 
and relative enzymatic activity localized to muscle 
remained significantly increased. These effects did 
not occur in athymic mice, suggesting a crucial role 
of T cells in the impairment of intestinal muscle 
function in post-infective disorders[30]. The role of 
COX-2 in muscle impairment during inflammation has 
been reported both in animal and humans. During 
severe mucosal inflammatory conditions, it has been 
shown in colonic muscle cells an altered expression of 
contractile key-signaling molecules and an increase 
in nuclear factor NF-kB DNA binding, which is low 
or absent in normal colonic muscle cells[31-33]. In 
human colonic smooth muscle, NF-kB activation leads 
to inflammatory gene expression of COX-2 and to 
production of prostaglandin E, both widely considered 
responsible for muscle cell impairment[34-37].
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Mediators released by the colonic mucosa of IBS 
patients are able to activate aberrant responses in the 
enteric nervous system[38,39] and to impair contractility 
of human colonic smooth muscle likely through 
a receptor-dependent mechanism[40]. Histamine 
and proteases, two soluble inflammatory products 
obtained from IBS biopsy supernatants, are able 
to excite visceral afferents neurons and to cause 
hyperalgesia and allodynia when introduced into the 
colon of mice[41,42]. Beside increased visceral sensory 
activation, the soluble products found in supernatants 
derived from the colon of IBS patients have been 
shown to evoke excitatory cholinergic longitudinal 
muscle contractions in the guinea pig ileum[43]. This 
effect correlates with the number of mast cells and the 
activation of the nerve fibers appears to be mediated 
by the activation of different receptors, including 
transient receptor potential vanilloid subfamily member 
1 (TRPV1), purinergic and prostanoids receptors[43].
Many studies have been conducted in attempt to 
identify a specific pattern of intestinal faecal microbiota 
in IBS patients and, although heterogeneity of IBS 
patients, qualitative and quantitative alterations in 
intestinal microflora have been found. Differently from 
traditional microbial culture-based techniques, studies 
using DNA-based techniques showed that specific fecal 
and mucosal microbiota composition are associated 
with different subgroups of IBS patients, even if 
these investigations have produced non univocal 
results. Some studies reported increased abundance 
of Proteobacteria and Firmicutes and reduction in 
Actinobacteria and Bacteroidetes in patients with 
IBS[11,44] while others reported a decreased amount of 
Lactobacilli and Bifidobacteria[45]. A very recent meta-
analysis demonstrated that composition of IBS patients 
microbiota vary across geographical regions. The study 
reported a decreased numbers of Bifidobacteria and 
Lactobacillus and increased numbers of Escherichia coli 
and Enterobacterium in Chinese IBS patients with no 
significant differences in the abundance of Bacteroides 
and Enterococcus. On the other hand, a decreased 
numbers of Bifidobacteria and increased numbers of 
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Figure 1  Dysbiosis and intestinal motility disorders. One hypothesis regarding the pathogenesis of functional intestinal disorders suggests that dysbiosis 
increases paracellular permeability leading to translocation of luminal contents with activation of immunocytes, cytokines and inflammatory mediators release. The 
activation of this state of inflammation and the presence of bacterial components, such as LPS, lead to nociceptive hypersensitivity, thus explaining the pain, and to 
enteric nervous system (ENS) or muscle impairment, thus explaining the intestinal motor disorders. LPS: Lipopolysaccharide.
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Deconjugated bile salts, another bacterial meta-
bolite[57], have also been reported to affect gastro-
intestinal motility through activation of transmembrane 
G-protein coupled receptor (TGR5)[58]. In animals, 
TGR5 have been detected in inhibitory intestinal motor 
neurons and on gallbladder smooth muscle cells[59]. 
The direct activation of TGR5 causes relaxation of 
the smooth muscle cells and inhibition of gallbladder 
contractility resulting in gallbladder filling. In humans, 
treating normal gallbladder muscle cells with a hydro-
phobic bile acid, the tauro-chenodeoxycholic acid, 
results in impairment of contraction to cholecystokinin 
due to a significant reduction in receptor binding and 
an increase in inflammatory mediators and oxidative 
stress[60,61]. These latter abnormalities, observed also 
in gallstone patients, are prevented by treatment with 
the hydrophilic ursodeoxycholic acid[61,62].
Among microbiota compounds that might influence 
GI motility, there is tryptamine, a secondary metabolite 
resulting from the transformation of the aromatic 
amino acid tryptophan, that mimics the serotonin 
stimulatory effects on motility in ex vivo preparations 
of guinea pig ileum[63]. It is of note that most genes 
encoding amino-acid-metabolizing enzymes involved 
in the synthesis of neurotransmitters (catecholamines, 
serotonin/melatonin, acetylcholine) are present in 
the microbiota genome[64]. Commensal bacteria have 
also been shown to be a significant source of nitric 
oxide (NO), a key molecule in the control of gut motor 
functions[65].
Finally, fermentation by the anaerobic flora of 
the undigested polysaccharide fraction of certain 
carbohydrates generates gases, mostly hydrogen 
(H2) and methane (CH4). Even if clinical studies are 
still controversial, experimental evidence has been 
provided that methane is not an inert intestinal 
gas since it can affect the intestinal neuromuscular 
function[66]. In animal models, it has been shown 
that intestinal methane infusion slowed down small 
intestinal transit time and augmented ileal circular 
muscle contractile activity[66,67]. In turn, in an ex vivo 
experiment on guinea pig gut, H2 by itself has been 
reported to significantly shorten colonic transit times, 
this effect being restored by methane[68]. Finally, the 
resident sulfate-reducing bacteria produce hydrogen 
sulfide (H2S) that inhibits intestinal contractile activity 
acting on interstitial cells of Cajal and enteric extrinsic 
neurons[66]. The effects of fermentation products on GI 
motility are summarized in table 1.
Bacterial molecular components
One of the main mechanisms of bacterial recognition 
are toll-like receptors (TLRs) a family of pattern 
recognition receptors that are emerging as potential 
mediators between microbiota and the enteric 
neuromuscular apparatus. TLR-dependent signaling 
regulates structural integrity in both the myenteric and 
submucosal plexus[69,70]. The mRNA encoding for TLRs 
Bacteroides were found in IBS patients from other 
regions of the world[46]. The strict relationship between 
dysbiosis and GI motility in IBS need to be further 
elucidated as one of the major challenges in IBS is the 
absence of an animal model that fully represent this 
condition. 
DIRECT EFFECTS
New physiopathologic and therapeutic scenarios 
have arisen by the recent evidence highlighting that 
microbiota metabolic products or bacterial molecular 
components can directly affect enteric nerves and 
smooth muscle cells functions.
Fermentation products
The microbiota is a formidable metabolic “organ”, not 
only able to capture calories from food but also to 
elaborate a large amount of compounds such as short-
chain fatty acids (SCFAs), neurotransmitters homologs 
and gases that can act directly with the enteric 
neuromuscular apparatus[47]. 
SCFAs such as acetate, propionate, and butyrate are 
produced by bacterial fermentation of dietary fibers. 
SCFAs exert multiple beneficial effects and act both as 
signal transduction molecules, via G-protein coupled 
free fatty acid receptors (FFAR2, FFAR3, OLFR78, 
GPR109A) and regulators of gene expression[48]. 
Besides improving the intestinal environment, SCFAs 
directly affect various host peripheral tissues, generate 
potent motor responses and have a considerable 
role in regulating the propulsive activity of the gut, 
both in animal models and in humans. SCFAs, when 
administered into the human terminal ileum, have 
been shown to increase parietal tone and stimulate 
ileal propulsive contractions[49,50]. This compounds are 
suggested to act via either extrinsic or intrinsic afferent 
neurons which can ultimately stimulate myenteric 
cholinergic neurons[51]. Most of these responses are 
not observed in mucosal free preparations, suggesting 
that SCFAs receptors are located on mucosal EC 
cells. In particular, propionate acts on receptors in 
the mucosa causing the release of 5-HT from EC 
cells that activates, through 5-HT4 receptors on 
the endings of intrinsic primary afferent neurons, 
the enteric peristaltic reflex pathways[51]. In the rat 
distal colon, propionate causes also tonic contraction 
via prostaglandin release[52]. Similarly, butyrate and 
acetate may also affect GI motility through several 
mechanisms including direct effects on smooth muscle 
and myenteric neurons[53] and production of mucosal 
5-HT[54]. SCFAs receptors have been also localized 
in mucosal EC cells containing peptide YY that might 
represent another important messenger in transducing 
this contractile signal[55]. However, the effect of these 
metabolites still remain controversial; a recent human 
study found no significant differences in global motility 
index after intracolonic infusion of SCFAs[56].
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have been detected on neurons[71], glial[72] and smooth 
muscle cells[73]. TLR-2 activation on smooth muscle 
leads to the production of neurotrophins that enhance 
the structural and functional integrity of the enteric 
nervous system[74]. 
In acute inflammatory conditions an excessive 
increase of mucosal permeability leads to luminal 
bacteria/endotoxins translocation[75]. Bacteria or 
bacterial products can migrate from the intestinal 
lumen to mesenteric lymph nodes, or the circulation, 
due to the disruption of the normal host/flora 
equilibrium as reported in cirrhosis[76], inflammatory 
bowel diseases[77] and recently in diarrhea-predominant 
IBS patients[78].
Most evidence on the effects of bacterial com-
ponents on the neuromuscular apparatus derives 
from studies on lipopolysaccharide (LPS), the major 
component of the outer membrane of Gram-negative 
bacteria. Although the exact mechanisms whereby 
LPS is able to impair muscle contractility are still to be 
established, various targets have been demonstrated. 
LPS can directly activate muscular TLR4 inducing a 
time- and concentration-dependent impairment of 
contractility associated to cytoskeleton alterations, 
together with an intracellular oxidative imbalance 
as shown on human colonic smooth muscle cells[79] 
(Figure 2). Many of these effects persisted even after 
LPS withdrawn suggesting that motility dysfunction 
might play a pivotal role both during an acute infective 
process and after its resolution. In an experimental 
model that enables to stimulate human intestinal 
mucosa in a polarized fashion with LPS[37], it has 
been shown that LPS affects enteric contractility 
both through translocation from the mucosa and 
submucosa, with subsequent activation of TLR 
expressed in muscle, and through mucosal production 
of oxygen free radicals. LPS effects on human smooth 
muscle were reversed by the H2O2 scavenger catalase, 
by NFkB transcription inhibitors and by indomethacin, 
which blocks activation of COX2[37]. Besides, LPS 
can directly activate macrophages embedded within 
the intestinal muscularis externa that produce in-
flammatory mediators that indirectly alter smooth 
muscle contractility[80,81].
Interestingly, the expression of multiple TLRs 
receptors subtypes differentially activated by bacterial 
antigens on the enteric neuromuscular apparatus 
seems to allow a discrimination between pathogens 
and probiotics, as reported for both human enteric 
glial[72], smooth muscle cells[73,82]. The crosstalk 
between TLRs subtypes is emerging as an important 
regulatory defense mechanism also in neuromuscular 
apparatus[83]. On human colonic smooth muscle cells, 
it has been observed that the activation of TLR2, 
whose ligands are the components of the outer 
membrane of Gram-positive bacteria, prevents LPS-
induced muscular alterations. By interacting with this 
receptor, Lactobacillus rhamnosus GG (LGG) is able to 
reduce LPS-induced NFkB activation and inflammatory 
IL6 secretion cytokine and to restore the levels of 
secretion of anti-inflammatory cytokine IL10[82]. These 
in vitro studies support the recent evidence that 
indicates the neuromuscular apparatus as possible 
target for probiotics[13-15]. Escherichia coli strain Nissle 
1917 specifically modulates contractility of human 
colonic muscle strips[84], Lactobacillus species regulate 
jejunal motility[14], colonic neuron excitability[15] and 
attenuate post-infective muscle hypercontractility[85]. 
Bifidobacterium and Lactobacillus also alleviate visceral 
hypersensitivity and recover intestinal barrier function 
as well as inflammation[86]. Also in humans recent 
evidence further suggests that probiotics might be 
effective in neuro-motor disorders[87,88].
CONCLUSION
In summary, the current working hypothesis is that 
dysbiosis-driven mucosal alterations induce the 
production of several inflammatory/immune mediators 
which affect gut neuro-muscular functions suggesting 
a potential for disturbances in the microbiota to 
elicit directly intestinal dismotility or, if sustained, 
Table 1  Direct effect of bacterial fermentation products on gastrointestinal motility
Fermentation 
product
Effect on GI motility Mechanism Ref.
Short-chain fatty 
acids 
Increase of ileal tone and propulsive contractions Activation of G-protein coupled free fatty acid receptors 
(FFAR2, FFAR3, OLFR78, GPR109A)
[48-55]
Smooth muscle and myenteric neurons activation Release of 5-HT from EC cells
Release of prostaglandins
Deconjugated bile 
salts
Relaxation of gallbladder smooth muscle cells Activation of transmembrane G-protein coupled receptor [58-61]
Inhibition of gallbladder contractility Reduction in cholecystokinin receptor binding
Increase of inflammatory mediators and oxidative stress
Tryptamine Stimulation of ileum motility Synthesis of neurotransmitters [63-65]
Gases Decrease of small intestinal transit time Methane (CH4) production [66,67]
Augmented ileal circular muscle contractile activity
Shortening of colonic transit times Hydrogen (H2) production [68]
Inhibition of intestinal contractile activity Hydrogen sulfide (H2S) production [66]
GI: Gastrointestinal.
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to lead to chronic sensory-motor dysfunction. The 
understanding in these fields would hopefully open 
new therapeutic scenarios in GI disease with under-
lying neuromuscular disorders as manipulation of 
gut microbiota composition could also correct the 
mechanisms promoting development and maintenance 
of symptoms. 
REFERENCES 
1 Dukowicz AC, Lacy BE, Levine GM. Small intestinal bacterial 
overgrowth: a comprehensive review. Gastroenterol Hepatol (N Y) 
2007; 3: 112-122 [PMID: 21960820]
2 Vantrappen G ,  Janssens J, Hellemans J, Ghoos Y. The 
interdigestive motor complex of normal subjects and patients with 
bacterial overgrowth of the small intestine. J Clin Invest 1977; 59: 
1158-1166 [PMID: 864008 DOI: 10.1172/JCI108740]
3 Nieuwenhuijs VB, Verheem A, van Duijvenbode-Beumer H, 
Visser MR, Verhoef J, Gooszen HG, Akkermans LM. The role 
of interdigestive small bowel motility in the regulation of gut 
microflora, bacterial overgrowth, and bacterial translocation in rats. 
Ann Surg 1998; 228: 188-193 [PMID: 9712563 DOI: 10.1097/000
00658-199808000-00007]
4 Gunnarsdottir SA, Sadik R, Shev S, Simrén M, Sjövall H, Stotzer 
PO, Abrahamsson H, Olsson R, Björnsson ES. Small intestinal 
motility disturbances and bacterial overgrowth in patients with 
liver cirrhosis and portal hypertension. Am J Gastroenterol 
2003; 98 :  1362-1370 [PMID: 12818282 DOI: 10.1111/
j.1572-0241.2003.07475.x]
5 Strid H, Simrén M, Stotzer PO, Ringström G, Abrahamsson H, 
Björnsson ES. Patients with chronic renal failure have abnormal 
small intestinal motility and a high prevalence of small intestinal 
bacterial overgrowth. Digestion 2003; 67: 129-137 [PMID: 
12853724 DOI: 10.1159/000071292]
6 Kaye SA, Lim SG, Taylor M, Patel S, Gillespie S, Black CM. 
Small bowel bacterial overgrowth in systemic sclerosis: detection 
using direct and indirect methods and treatment outcome. Br J 
Rheumatol 1995; 34: 265-269 [PMID: 7728404 DOI: 10.1093/
rheumatology/34.3.265]
7 Armbrecht U, Lundell L, Lindstedt G, Stockbruegger RW. 
Causes of malabsorption after total gastrectomy with Roux-
en-Y reconstruction. Acta Chir Scand 1988; 154: 37-41 [PMID: 
3354282]
8 Q u i g l e y  E M .  M i c r o f l o r a  m o d u l a t i o n  o f  m o t i l i t y.  J 
Neurogastroenterol Motil 2011; 17: 140-147 [PMID: 21602990 
DOI: 10.5056/jnm.2011.17.2.140]
9 Barbara G, Stanghellini V, Brandi G, Cremon C, Di Nardo G, 
De Giorgio R, Corinaldesi R. Interactions between commensal 
bacteria and gut sensorimotor function in health and disease. Am 
J Gastroenterol 2005; 100: 2560-2568 [PMID: 16279914 DOI: 
10.1111/j.1572-0241.2005.00230.x]
10 Hooper LV, Wong MH, Thelin A, Hansson L, Falk PG, Gordon JI. 
Molecular analysis of commensal host-microbial relationships in 
the intestine. Science 2001; 291: 881-884 [PMID: 11157169 DOI: 
10.1126/science.291.5505.881]
11 Collins SM. A role for the gut microbiota in IBS. Nat Rev 
Gastroenterol Hepatol 2014; 11: 497-505 [PMID: 24751910 DOI: 
10.1038/nrgastro.2014.40]
12 Foxx-Orenstein AE, Chey WD. Manipulation of the Gut 
Microbiota as a Novel Treatment Strategy for Gastrointestinal 
Disorders. Am J Gastroenterol Suppl 2012; 1: 41-46 [DOI: 
10.1038/ajgsup.2012.8]
13 Massi M, Ioan P, Budriesi R, Chiarini A, Vitali B, Lammers KM, 
Gionchetti P, Campieri M, Lembo A, Brigidi P. Effects of probiotic 
bacteria on gastrointestinal motility in guinea-pig isolated tissue. 
World J Gastroenterol 2006; 12: 5987-5994 [PMID: 17009397 
DOI: 10.3748/wjg.v12.i37.5987]
14 Wang B, Mao YK, Diorio C, Pasyk M, Wu RY, Bienenstock J, 
Kunze WA. Luminal administration ex vivo of a live Lactobacillus 
species moderates mouse jejunal motility within minutes. 
LPS
LPS
LGG
TL
R2
TL
R4
NFkB activation PGE2
H2O2
H2O2
Rec
G prot
ACh
Intestinal lumen
Oxidative stress
Mucosa
submucosa
Contractile proteins
Ca2+
Ca
2+
+ -
Figure 2  Role of toll-like receptors on human colonic smooth muscle cells. LPS affects intestinal contractility by activating oxidative stress in the mucosa and, 
once translocated, by activating TLR4 expressed in colonic muscle cells. Activation of muscular TLR4 impairs cell contractility by activation of the nuclear factor kB 
transcription with intracellular increase of oxidative stress and by prostaglandin E2 (PGE2) that block intracellular calcium release. The oxygen free radicals, produced 
in the mucosa, impair cell contractility with a similar mechanism and also by de-regulation of contractile receptors. The activation of TLR2, whose ligands are the 
components of the outer membrane of Gram-positive bacteria, such Lactobacillus rhamnosus GG (LGG), prevents LPS-induced muscular alterations. TLR4: Toll-like 
receptor 4; LPS: Lipopolysaccharide.
Guarino MPL et al . Microbiota and intestinal motility
9877 December 7, 2016|Volume 22|Issue 45|WJG|www.wjgnet.com
FASEB J 2010; 24: 4078-4088 [PMID: 20519636 DOI: 10.1096/
fj.09-153841]
15 Kunze WA, Mao YK, Wang B, Huizinga JD, Ma X, Forsythe 
P, Bienenstock J. Lactobacillus reuteri enhances excitability of 
colonic AH neurons by inhibiting calcium-dependent potassium 
channel opening. J Cell Mol Med 2009; 13: 2261-2270 [PMID: 
19210574 DOI: 10.1111/j.1582-4934.2009.00686.x]
16 Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota 
in health and disease. Physiol Rev 2010; 90: 859-904 [PMID: 
20664075 DOI: 10.1152/physrev.00045.2009]
17 Barbara G, Zecchi L, Barbaro R, Cremon C, Bellacosa L, 
Marcellini M, De Giorgio R, Corinaldesi R, Stanghellini V. 
Mucosal permeability and immune activation as potential 
therapeutic targets of probiotics in irritable bowel syndrome. J Clin 
Gastroenterol 2012; 46 Suppl: S52-S55 [PMID: 22955358 DOI: 
10.1097/MCG.0b013e318264e918]
18 Simrén M, Barbara G, Flint HJ, Spiegel BM, Spiller RC, Vanner 
S, Verdu EF, Whorwell PJ, Zoetendal EG. Intestinal microbiota in 
functional bowel disorders: a Rome foundation report. Gut 2013; 
62: 159-176 [PMID: 22730468 DOI: 10.1136/gutjnl-2012-302167]
19 Minemura M, Shimizu Y. Gut microbiota and liver diseases. 
World J Gastroenterol 2015; 21: 1691-1702 [PMID: 25684933 
DOI: 10.3748/wjg.v21.i6.1691]
20 Fukui H. Gut-liver axis in liver cirrhosis: How to manage leaky 
gut and endotoxemia. World J Hepatol 2015; 7: 425-442 [PMID: 
25848468 DOI: 10.4254/wjh.v7.i3.425]
21 Thabane M, Kottachchi DT, Marshall JK. Systematic re-
view and meta-analysis: The incidence and prognosis of post-
infectious irritable bowel syndrome. Aliment Pharmacol 
Ther 2007; 26: 535-544 [PMID: 17661757 DOI: 10.1111/
j.1365-2036.2007.03399.x]
22 Tam CC, Rodrigues LC, Viviani L, Dodds JP, Evans MR, Hunter 
PR, Gray JJ, Letley LH, Rait G, Tompkins DS, O’Brien SJ. 
Longitudinal study of infectious intestinal disease in the UK (IID2 
study): incidence in the community and presenting to general 
practice. Gut 2012; 61: 69-77 [PMID: 21708822 DOI: 10.1136/
gut.2011.238386]
23 Barbara G, Cremon C, Carini G, Bellacosa L, Zecchi L, De 
Giorgio R, Corinaldesi R, Stanghellini V. The immune system in 
irritable bowel syndrome. J Neurogastroenterol Motil 2011; 17: 
349-359 [PMID: 22148103 DOI: 10.5056/jnm.2011.17.4.349]
24 Lee YJ, Park KS. Irritable bowel syndrome: emerging paradigm 
in pathophysiology. World J Gastroenterol 2014; 20: 2456-2469 
[PMID: 24627583 DOI: 10.3748/wjg.v20.i10.2456]
25 Spiller R, Lam C. An Update on Post-infectious Irritable Bowel 
Syndrome: Role of Genetics, Immune Activation, Serotonin 
and Altered Microbiome. J Neurogastroenterol Motil 2012; 18: 
258-268 [PMID: 22837873 DOI: 10.5056/jnm.2012.18.3.258]
26 Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative 
factor of irritable bowel syndrome and its pathogenesis. Gut 2004; 
53: 1096-1101 [PMID: 15247174 DOI: 10.1136/gut.2003.021154]
27 Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, 
Skinner M, Neal KR. Increased rectal mucosal enteroendocrine 
cells, T lymphocytes, and increased gut permeability following 
acute Campylobacter enteritis and in post-dysenteric irritable 
bowel syndrome. Gut 2000; 47: 804-811 [PMID: 11076879 DOI: 
10.1136/gut.47.6.804]
28 Coates MD, Mahoney CR, Linden DR, Sampson JE, Chen J, 
Blaszyk H, Crowell MD, Sharkey KA, Gershon MD, Mawe GM, 
Moses PL. Molecular defects in mucosal serotonin content and 
decreased serotonin reuptake transporter in ulcerative colitis and 
irritable bowel syndrome. Gastroenterology 2004; 126: 1657-1664 
[PMID: 15188158 DOI: 10.1053/j.gastro.2004.03.013]
29 Crowell MD, Shetzline MA, Moses PL, Mawe GM, Talley NJ. 
Enterochromaffin cells and 5-HT signaling in the pathophysiology 
of disorders of gastrointestinal function. Curr Opin Investig Drugs 
2004; 5: 55-60 [PMID: 14983974]
30 Barbara G, De Giorgio R, Deng Y, Vallance B, Blennerhassett 
P, Collins SM. Role of immunologic factors and cyclooxygenase 
2 in persistent postinfective enteric muscle dysfunction in mice. 
Gastroenterology 2001; 120: 1729-1736 [PMID: 11375954]
31 Shi XZ, Lindholm PF, Sarna SK. NF-kappa B activation by 
oxidative stress and inflammation suppresses contractility in 
colonic circular smooth muscle cells. Gastroenterology 2003; 124: 
1369-1380 [PMID: 12730877 DOI: 10.1053/gast.2001.24847]
32 Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor 
kappa B inflammatory bowel disease. Gut 1998; 42: 477-484 
[PMID: 9616307 DOI: 10.1136/gut.42.4.477]
33 Funakoshi T, Yamashita K, Ichikawa N, Fukai M, Suzuki 
T, Goto R, Oura T, Kobayashi N, Katsurada T, Ichihara S, 
Ozaki M, Umezawa K, Todo S. A novel NF-κB inhibitor, 
dehydroxymethylepoxyquinomicin, ameliorates inflammatory 
colonic injury in mice. J Crohns Colitis 2012; 6: 215-225 [PMID: 
22325176 DOI: 10.1016/j.crohns.2011.08.011]
34 Salinthone S, Singer CA, Gerthoffer WT. Inflammatory gene 
expression by human colonic smooth muscle cells. Am J Physiol 
Gastrointest Liver Physiol 2004; 287: G627-G637 [PMID: 
15117678 DOI: 10.1152/ajpgi.00462.2003]
35 Khan I, Oriowo MA. Mechanism underlying the reversal 
of contracti l i ty dysfunction in experimental colit is  by 
cyclooxygenase-2 inhibition. Inflammopharmacology 2006; 14: 
28-35 [PMID: 16835710 DOI: 10.1007/s10787-006-1507-7]
36 Rebollar E, Arruebo MP, Plaza MA, Murillo MD. Effect 
of lipopolysaccharide on rabbit small intestine muscle 
contractility in vitro: role of prostaglandins. Neurogastroenterol 
Motil 2002; 14: 633-642 [PMID: 12464085 DOI: 10.1046/
j.1365-2982.2002.00364.x]
37 Guarino MP, Sessa R, Altomare A, Cocca S, Di Pietro M, Carotti 
S, Schiavoni G, Alloni R, Emerenziani S, Morini S, Severi C, 
Cicala M. Human colonic myogenic dysfunction induced by 
mucosal lipopolysaccharide translocation and oxidative stress. Dig 
Liver Dis 2013; 45: 1011-1016 [PMID: 23891549 DOI: 10.1016/
j.dld.2013.06.001]
38 Barbara G, Wang B, Stanghellini V, de Giorgio R, Cremon C, Di 
Nardo G, Trevisani M, Campi B, Geppetti P, Tonini M, Bunnett 
NW, Grundy D, Corinaldesi R. Mast cell-dependent excitation of 
visceral-nociceptive sensory neurons in irritable bowel syndrome. 
Gastroenterology 2007; 132: 26-37 [PMID: 17241857 DOI: 
10.1053/j.gastro.2006.11.039]
39 Nasser Y, Boeckxstaens GE, Wouters MM, Schemann M, Vanner 
S. Using human intestinal biopsies to study the pathogenesis of 
irritable bowel syndrome. Neurogastroenterol Motil 2014; 26: 
455-469 [PMID: 24602069 DOI: 10.1111/nmo.12316]
40 Guarino MP, Barbara G, Cicenia A, Altomare A, Barbaro MR, 
Cocca S, Scirocco A, Cremon C, Emerenziani S, Stanghellini V, 
Cicala M, Severi C. Supernatants of irritable bowel syndrome 
mucosal biopsies impair human colonic smooth muscle 
contractility. Neurogastroenterol Motil 2016; Epub ahead of print 
[PMID: 27619727 DOI: 10.1111/nmo.12928]
41 Cenac N, Andrews CN, Holzhausen M, Chapman K, Cottrell G, 
Andrade-Gordon P, Steinhoff M, Barbara G, Beck P, Bunnett NW, 
Sharkey KA, Ferraz JG, Shaffer E, Vergnolle N. Role for protease 
activity in visceral pain in irritable bowel syndrome. J Clin Invest 
2007; 117: 636-647 [PMID: 17304351 DOI: 10.1172/JCI29255]
42 Buhner S, Li Q, Berger T, Vignali S, Barbara G, De Giorgio R, 
Stanghellini V, Schemann M. Submucous rather than myenteric 
neurons are activated by mucosal biopsy supernatants from 
irritable bowel syndrome patients. Neurogastroenterol Motil 2012; 
24: 1134-e572 [PMID: 22963673 DOI: 10.1111/nmo.12011]
43 Balestra B, Vicini R, Cremon C, Zecchi L, Dothel G, Vasina V, De 
Giorgio R, Paccapelo A, Pastoris O, Stanghellini V, Corinaldesi R, 
De Ponti F, Tonini M, Barbara G. Colonic mucosal mediators from 
patients with irritable bowel syndrome excite enteric cholinergic 
motor neurons. Neurogastroenterol Motil 2012; 24: 1118-e570 
[PMID: 22937879 DOI: 10.1111/nmo.12000]
44 Krogius-Kurikka L, Lyra A, Malinen E, Aarnikunnas J, Tuimala 
J, Paulin L, Mäkivuokko H, Kajander K, Palva A. Microbial 
community analysis reveals high level phylogenetic alterations in 
the overall gastrointestinal microbiota of diarrhoea-predominant 
irritable bowel syndrome sufferers. BMC Gastroenterol 2009; 9: 95 
Guarino MPL et al . Microbiota and intestinal motility
9878 December 7, 2016|Volume 22|Issue 45|WJG|www.wjgnet.com
[PMID: 20015409 DOI: 10.1186/1471-230X-9-95]
45 Distrutti E, Monaldi L, Ricci P, Fiorucci S. Gut microbiota role 
in irritable bowel syndrome: New therapeutic strategies. World 
J Gastroenterol 2016; 22: 2219-2241 [PMID: 26900286 DOI: 
10.3748/wjg.v22.i7.2219]
46 Zhuang X, Xiong L, Li L, Li M, Chen MH. Alterations of gut 
microbiota in patients with irritable bowel syndrome: A systematic 
review and meta-analysis. J Gastroenterol Hepatol 2016; Epub 
ahead of print [PMID: 27300149 DOI: 10.1111/jgh.13471]
47 Mayer EA, Tillisch K, Gupta A. Gut/brain axis and the microbiota. 
J Clin Invest 2015; 125: 926-938 [PMID: 25689247 DOI: 10.1172/
JCI76304]
48 Kasubuchi M, Hasegawa S, Hiramatsu T, Ichimura A, Kimura 
I. Dietary gut microbial metabolites, short-chain fatty acids, and 
host metabolic regulation. Nutrients 2015; 7: 2839-2849 [PMID: 
25875123 DOI: 10.3390/nu7042839]
49 Coffin B, Lémann M, Flourié B, Jouet P, Rambaud JC, Jian R. 
Local regulation of ileal tone in healthy humans. Am J Physiol 
1997; 272: G147-G153 [PMID: 9038888]
50 Kamath PS, Phillips SF, Zinsmeister AR. Short-chain fatty 
acids stimulate ileal motility in humans. Gastroenterology 
1988;  95 :  1496-1502 [PMID: 3181675 DOI:  10.1016/
S0016-5085(88)80068-4]
51 Grider JR, Piland BE. The peristaltic reflex induced by short-
chain fatty acids is mediated by sequential release of 5-HT and 
neuronal CGRP but not BDNF. Am J Physiol Gastrointest Liver 
Physiol 2007; 292: G429-G437 [PMID: 16973914 DOI: 10.1152/
ajpgi.00376.2006]
52 Mitsui R, Ono S, Karaki S, Kuwahara A. Neural and non-neural 
mediation of propionate-induced contractile responses in the rat 
distal colon. Neurogastroenterol Motil 2005; 17: 585-594 [PMID: 
16078948 DOI: 10.1111/j.1365-2982.2005.00669.x]
53 Haschke G, Schafer H, Diener M. Effect of butyrate on membrane 
potential, ionic currents and intracellular Ca2+ concentration 
in cultured rat myenteric neurones. Neurogastroenterol 
Motil 2002; 14: 133-142 [PMID: 11975713 DOI: 10.1046/
j.1365-2982.2002.00312.x]
54 Fukumoto S, Tatewaki M, Yamada T, Fujimiya M, Mantyh C, 
Voss M, Eubanks S, Harris M, Pappas TN, Takahashi T. Short-
chain fatty acids stimulate colonic transit via intraluminal 
5-HT release in rats. Am J Physiol Regul Integr Comp Physiol 
2003; 284: R1269-R1276 [PMID: 12676748 DOI: 10.1152/
ajpregu.00442.2002]
55 Tazoe H, Otomo Y, Karaki S, Kato I, Fukami Y, Terasaki M, 
Kuwahara A. Expression of short-chain fatty acid receptor GPR41 
in the human colon. Biomed Res 2009; 30: 149-156 [PMID: 
19574715 DOI: 10.2220/biomedres.30.149]
56 Jouët P, Moussata D, Duboc H, Boschetti G, Attar A, Gorbatchef 
C, Sabaté JM, Coffin B, Flourié B. Effect of short-chain fatty acids 
and acidification on the phasic and tonic motor activity of the 
human colon. Neurogastroenterol Motil 2013; 25: 943-949 [PMID: 
24033744 DOI: 10.1111/nmo.12212]
57 Sayin SI, Wahlström A, Felin J, Jäntti S, Marschall HU, Bamberg 
K, Angelin B, Hyötyläinen T, Orešič M, Bäckhed F. Gut 
microbiota regulates bile acid metabolism by reducing the levels of 
tauro-beta-muricholic acid, a naturally occurring FXR antagonist. 
Cell Metab 2013; 17: 225-235 [PMID: 23395169 DOI: 10.1016/
j.cmet.2013.01.003]
58 Penney NC, Kinross J, Newton RC, Purkayastha S. The role of 
bile acids in reducing the metabolic complications of obesity after 
bariatric surgery: a systematic review. Int J Obes (Lond) 2015; 39: 
1565-1574 [PMID: 26081915 DOI: 10.1038/ijo.2015.115]
59 Lavoie B, Balemba OB, Godfrey C, Watson CA, Vassileva G, 
Corvera CU, Nelson MT, Mawe GM. Hydrophobic bile salts inhibit 
gallbladder smooth muscle function via stimulation of GPBAR1 
receptors and activation of KATP channels. J Physiol 2010; 588: 
3295-3305 [PMID: 20624794 DOI: 10.1113/jphysiol.2010.192146]
60 Parkman HP, Bogar LJ, Bartula LL, Pagano AP, Thomas 
RM, Myers SI. Effect of experimental acalculous cholecystitis 
on gallbladder smooth muscle contractility. Dig Dis Sci 1999; 
44: 2235-2243 [PMID: 10573368 DOI: 10.1016/S0016-
5085(98)82180-X]
61 Guarino MP, Cong P, Cicala M, Alloni R, Carotti S, Behar 
J. Ursodeoxycholic acid improves muscle contractility and 
inflammation in symptomatic gallbladders with cholesterol 
gallstones. Gut 2007; 56: 815-820 [PMID: 17185355 DOI: 
10.1136/gut.2006.109934]
62 Guarino MP, Carotti S, Morini S, Perrone G, Behar J, Altomare 
A, Alloni R, Caviglia R, Emerenziani S, Rabitti C, Cicala M. 
Decreased number of activated macrophages in gallbladder muscle 
layer of cholesterol gallstone patients following ursodeoxycholic 
acid. Gut 2008; 57: 1740-1741 [PMID: 19022933 DOI: 10.1136/
gut.2008.160333]
63 Takaki M, Mawe GM, Barasch JM, Gershon MD, Gershon 
MD. Physiological responses of guinea-pig myenteric neurons 
secondary to the release of endogenous serotonin by tryptamine. 
Neuroscience 1985; 16: 223-240 [PMID: 2940472 DOI: 10.1016/0
306-4522(85)90059-4]
64 Iyer LM, Aravind L, Coon SL, Klein DC, Koonin EV. Evolution 
of cell-cell signaling in animals: did late horizontal gene transfer 
from bacteria have a role? Trends Genet 2004; 20: 292-299 [PMID: 
15219393 DOI: 10.1016/j.tig.2004.05.007]
65 Sobko T, Huang L, Midtvedt T, Norin E, Gustafsson LE, Norman 
M, Jansson EA, Lundberg JO. Generation of NO by probiotic 
bacteria in the gastrointestinal tract. Free Radic Biol Med 2006; 41: 
985-991 [PMID: 16934682 DOI: 10.1016/j.freeradbiomed.2006.06
.020]
66 Triantafyllou K, Chang C, Pimentel M. Methanogens, methane 
and gastrointestinal motility. J Neurogastroenterol Motil 2014; 20: 
31-40 [PMID: 24466443 DOI: 10.5056/jnm.2014.20.1.31]
67 Pimentel M, Lin HC, Enayati P, van den Burg B, Lee HR, Chen 
JH, Park S, Kong Y, Conklin J. Methane, a gas produced by enteric 
bacteria, slows intestinal transit and augments small intestinal 
contractile activity. Am J Physiol Gastrointest Liver Physiol 
2006; 290: G1089-G1095 [PMID: 16293652 DOI: 10.1152/
ajpgi.00574.2004]
68 Jahng J, Jung IS, Choi EJ, Conklin JL, Park H. The effects 
of methane and hydrogen gases produced by enteric bacteria 
on ileal motility and colonic transit time. Neurogastroenterol 
Motil 2012; 24: 185-190, e92 [PMID: 22097886 DOI: 10.1111/
j.1365-2982.2011.01819.x]
69 Kamada N, Kao JY. The tuning of the gut nervous system by 
commensal microbiota. Gastroenterology 2013; 145: 1193-1196 
[PMID: 24409480 DOI: 10.1053/j.gastro.2013.10.036]
70 Anitha M, Vijay-Kumar M, Sitaraman SV, Gewirtz AT, Srinivasan 
S. Gut microbial products regulate murine gastrointestinal motility 
via Toll-like receptor 4 signaling. Gastroenterology 2012; 143: 
1006-1016.e4 [PMID: 22732731 DOI: 10.1053/j.gastro.2012.06.034]
71 Barajon I, Serrao G, Arnaboldi F, Opizzi E, Ripamonti G, Balsari 
A, Rumio C. Toll-like receptors 3, 4, and 7 are expressed in the 
enteric nervous system and dorsal root ganglia. J Histochem 
Cytochem 2009; 57: 1013-1023 [PMID: 19546475 DOI: 10.1369/
jhc.2009.953539]
72 Turco F, Sarnelli G, Cirillo C, Palumbo I, De Giorgi F, D’
Alessandro A, Cammarota M, Giuliano M, Cuomo R. Enteroglial-
derived S100B protein integrates bacteria-induced Toll-like 
receptor signalling in human enteric glial cells. Gut 2014; 63: 
105-115 [PMID: 23292665 DOI: 10.1136/gutjnl-2012-302090]
73 Tattoli I, Petitta C, Scirocco A, Ammoscato F, Cicenia A, Severi 
C. Microbiota, innate immune system, and gastrointestinal muscle: 
ongoing studies. J Clin Gastroenterol 2012; 46 Suppl: S6-11 
[PMID: 22955360 DOI: 10.1097/MCG.0b013e318265ea7d]
74 Brun P, Gobbo S, Caputi V, Spagnol L, Schirato G, Pasqualin M, 
Levorato E, Palù G, Giron MC, Castagliuolo I. Toll like receptor-2 
regulates production of glial-derived neurotrophic factors in murine 
intestinal smooth muscle cells. Mol Cell Neurosci 2015; 68: 24-35 
[PMID: 25823690 DOI: 10.1016/j.mcn.2015.03.018]
75 Berg RD. Bacterial translocation from the gastrointestinal tract. 
Adv Exp Med Biol 1999; 473: 11-30 [PMID: 10659341 DOI: 
10.1016/S0966-842X(00)88906-4]
Guarino MPL et al . Microbiota and intestinal motility
9879 December 7, 2016|Volume 22|Issue 45|WJG|www.wjgnet.com
76 Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. 
Hepatology 2005; 41: 422-433 [PMID: 15723320 DOI: 10.1002/
hep.20632]
77 Pastor Rojo O, López San Román A, Albéniz Arbizu E, de la 
Hera Martínez A, Ripoll Sevillano E, Albillos Martínez A. Serum 
lipopolysaccharide-binding protein in endotoxemic patients 
with inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 
269-277 [PMID: 17206721 DOI: 10.1002/ibd.20019]
78 Dlugosz A, Nowak P, D’Amato M, Mohammadian Kermani 
G, Nyström J, Abdurahman S, Lindberg G. Increased serum 
levels of lipopolysaccharide and antiflagellin antibodies in 
patients with diarrhea-predominant irritable bowel syndrome. 
Neurogastroenterol Motil 2015; 27: 1747-1754 [PMID: 26387872 
DOI: 10.1111/nmo.12670]
79 Matarrese P, Petitta C, Scirocco A, Ascione B, Ammoscato F, Di 
Natale G, Anastasi E, Marconi M, Chirletti P, Malorni W, Severi 
C. Antioxidants counteract lipopolysaccharide-triggered alterations 
of human colonic smooth muscle cells. Free Radic Biol Med 2012; 
53: 2102-2111 [PMID: 23044262 DOI: 10.1016/j.freeradbiomed.2
012.09.022]
80 Eskandari MK, Kalff JC, Billiar TR, Lee KK, Bauer AJ. LPS-
induced muscularis macrophage nitric oxide suppresses rat jejunal 
circular muscle activity. Am J Physiol 1999; 277: G478-G486 
[PMID: 10444463]
81 Muller PA, Koscsó B, Rajani GM, Stevanovic K, Berres ML, 
Hashimoto D, Mortha A, Leboeuf M, Li XM, Mucida D, Stanley 
ER, Dahan S, Margolis KG, Gershon MD, Merad M, Bogunovic 
M. Crosstalk between muscularis macrophages and enteric neurons 
regulates gastrointestinal motility. Cell 2014; 158: 300-313 [PMID: 
25036630 DOI: 10.1016/j.cell.2014.04.050]
82 Ammoscato F, Scirocco A, Altomare A, Matarrese P, Petitta C, 
Ascione B, Caronna R, Guarino M, Marignani M, Cicala M, 
Chirletti P, Malorni W, Severi C. Lactobacillus rhamnosus protects 
human colonic muscle from pathogen lipopolysaccharide-induced 
damage. Neurogastroenterol Motil 2013; 25: 984-e777 [PMID: 
24118564 DOI: 10.1111/nmo.12232]
83 Kotaki R, Wajima S, Shiokawa A, Hachimura S. Toll-like 
receptor 2 suppresses Toll-like receptor 9 responses in Peyer’s 
patch dendritic cells. Immunobiology 2015; 220: 734-743 [PMID: 
25638261 DOI: 10.1016/j.imbio.2014.12.022]
84 Bär F, Von Koschitzky H, Roblick U, Bruch HP, Schulze L, 
Sonnenborn U, Böttner M, Wedel T. Cell-free supernatants of 
Escherichia coli Nissle 1917 modulate human colonic motility: 
evidence from an in vitro organ bath study. Neurogastroenterol 
Motil 2009; 21: 559-66, e16-17 [PMID: 19220758 DOI: 10.1111/
j.1365-2982.2008.01258.x]
85 Verdú EF, Bercík P, Bergonzelli GE, Huang XX, Blennerhasset 
P, Rochat F, Fiaux M, Mansourian R, Corthésy-Theulaz I, Collins 
SM. Lactobacillus paracasei normalizes muscle hypercontractility 
in  a  mur ine  model  of  pos t infec t ive  gut  dysfunct ion . 
Gastroenterology 2004; 127: 826-837 [PMID: 15362038 DOI: 
10.1053/j.gastro.2004.06.007]
86 Wang H, Gong J, Wang W, Long Y, Fu X, Fu Y, Qian W, Hou X. 
Are there any different effects of Bifidobacterium, Lactobacillus 
and Streptococcus on intestinal sensation, barrier function and 
intestinal immunity in PI-IBS mouse model? PLoS One 2014; 9: 
e90153 [PMID: 24595218 DOI: 10.1371/journal.pone.0090153]
87 Kim SE, Choi SC, Park KS, Park MI, Shin JE, Lee TH, Jung KW, 
Koo HS, Myung SJ. Change of Fecal Flora and Effectiveness 
of the Short-term VSL#3 Probiotic Treatment in Patients With 
Functional Constipation. J Neurogastroenterol Motil 2015; 21: 
111-120 [PMID: 25537674 DOI: 10.5056/jnm14048]
88 Didari T, Mozaffari S, Nikfar S, Abdollahi M. Effectiveness of 
probiotics in irritable bowel syndrome: Updated systematic review 
with meta-analysis. World J Gastroenterol 2015; 21: 3072-3084 
[PMID: 25780308 DOI: 10.3748/wjg.v21.i10.3072]
P- Reviewer: Dumitrascu DL, Plaza MA, Xu WX 
S- Editor: Gong ZM    L- Editor: A    E- Editor: Wang CH
Guarino MPL et al . Microbiota and intestinal motility
                                      © 2016 Baishideng Publishing Group Inc. All rights reserved.
Published by Baishideng Publishing Group Inc
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
http://www.wjgnet.com
I S S N  1 0  0 7  -   9  3 2  7
9    7 7 1 0  07   9 3 2 0 45
4   5
